RCA Telegram News California - Ainos Updates Standard Industrial Classification Code to Reflect Smell AI Business Focus

HOUSTON, TX / ACCESS Newswire / May 11, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it updated its Standard Industrial Classification ("SIC") code from SIC 2834 - Pharmaceutical Preparations to SIC 3577 - Computer Peripheral Equipment, NEC. We believe the updated classification reflects Ainos' operational evolution and commercialization focus on AI-powered sensing, industrial AI applications, and Smell AI technologies driven by AI Nose, the Company's proprietary AI-powered scent digitization platform.

AI Nose converts volatile organic compound ("VOC") and scent signals into machine-readable Smell ID data using proprietary artificial intelligence models, including Smell Language Model ("SLM"), and integrated sensor technologies. Ainos is advancing commercial deployments and commercialization initiatives for the platform across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments.

"We believe the updated industry classification reflects the continued evolution of our business from healthcare-originated applications toward AI-powered sensing and environmental intelligence technologies," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "As we expand commercial deployments across semiconductor, robotics, smart infrastructure, and healthcare-related environments, we believe AI Nose is positioning Ainos at the intersection of AI, digital olfaction, and real-world industrial intelligence."

Ainos is also classified under the Global Industry Classification Standard (GICS®) within Technology Hardware, Storage & Peripherals (Code 45202030).

Standard Industrial Classification ("SIC") codes categorize companies based on their primary business activities and support industry classification, market research, financial databases, and comparative analysis across public companies. The SIC-code update does not, in itself, change the Company's business operations, financial condition, SEC reporting obligations, Nasdaq listing status, ticker symbols, long-term strategy, or the risks associated with the Company's business.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.

About Ainos, Inc.

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA^®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information
Investor Relations
[email protected]

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

P.Batteux--RTC